Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Resubmission Acknowledgement Letter - Berinert, June 30, 2009

Our STN:  BL 125287/0

CSL Behring GmbH
Attention:  Paul Hartmann, R.Ph.
1020 First Avenue
P.O. Box 61501

King of Prussia, PA  19406-0901

Dear Mr. Hartmann:


We have received your April 8, 2009 resubmission to your biologics license application for C1 Esterase Inhibitor (Human) on April 10, 2009.


The resubmission contains additional CMC and clinical information that you submitted in response to our December 5, 2008 complete response letter.


We consider this a complete, class 2 response to our action letter.  Therefore, the user fee goal date is October 10, 2009.


If you have any questions, please contact the Regulatory Project Manager, Nannette Cagungun, at 827-6174.


Sincerely yours,


Basil Golding, M.D.
Division of Hematology
Office of Blood
  Research and Review
Center for Biologics
  Evaluation and Research

Page Last Updated: 04/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English